At least three reports related to CF NBS have been published: a study of the clinical characteristics of Polish patients with rare and novel CFTR mutations to determine their pathogenicity [953]; a 10-year review of the impact of NBS on clinical outcomes of pediatric patients in Lodz Voivodeship [954]; and an investigation into the clinical complications in children with late-diagnosed (false-negative) CF (with a reminder that, “in the presence of clinical symptoms, additional diagnostics must be implemented, in spite of the negative screening results”). This evidence concerns the gene CFTR and cystic fibrosis.